Biotechnology company Omega Therapeutics, developing gene therapy for cancer and other diseases in the preclinical stage of research, attracted 126 million dollars, releasing 7,4 million shares in 17 dollars - within the stated range from 16 to 18 Dollars. Taking into account the actual IPO price, the total diluted market value of the company was 866 million dollars.
Omega Therapeutics, specializing in gene therapy, conducted an IPO at an average price
Omega Therapeutics plans to use OMEGA's proprietary epigenomic programming platform to create a new class of therapeutic agents, targeting the DNA sequence and encoded mRNA. The company's product line includes preclinical programs in the field of regenerative medicine and multigenic diseases, including immunology, Oncology, and some monogenic diseases. The company has conducted in vivo preclinical studies in hepatocellular carcinoma, non-small cell lung cancer and acute respiratory distress syndrome.
Omega Therapeutics plans to list on the stock exchange Nasdaq under the ticker OMGA. Goldman Sachs became the joint organizers of the share issue, Jefferies, Piper Sandler и Wedbush PacGrow.
